EFPIA - NEWSLETTER

EFPIA Newsletter 19 June 2025

Blogs

18 June 2025 Working together to build a better Product Information Leaflet (Guest blog)

In response to the evolving landscape of electronic Product Information (ePI) and the currently ongoing revision of...

EU-X-CT final recommendations now available

The EU-X-CT Recommendations on Cross-Border Access to Clinical Trials have been published this week, following collaboration among over 100 experts from patient organisations, academia, regulatory bodies, and industry.

Coordinated by EFGCP and EFPIA, the recommendations aim to enhance access to clinical trials for participants across European borders. Covering legal and ethical considerations, site readiness, and patient support, the guidance offers practical insights for all involved in cross-border trials.

Join us at the EU-X-CT Stakeholder Conference on 24 June 2025 to further explore these topics.

Launch of the IHI Call 11

The IHI Call 11 was officially launched on 17 June. EFPIA is proud to support this new call that brings public and private sectors together to address some of the most pressing health challenges.

Get details of the topics and how to apply here. Deadline for short proposals: 9 October 2025

Events

24 JUN 2025

Virtual Dialogue - The critical role of data in addressing antimicrobial resistance... Virtual event

Data on the impact of antimicrobial resistance (AMR) on cancer care is scarce. To effectively address this issue, it...

Learn more →

01 JUL 2025

Nordic Rare Diseases Roadmap - EU Launch Brussels, Belgium

The Nordic Rare Diseases Roadmap will be launched on 1 July at the European Parliament. Co-hosted by MEP Stine Bosse...

Learn more →

IMI & IHI: Accelerating health innovation

In today’s evolving health research landscape, public private collaboration is key to driving impactful innovation. They deliver results to optimise the R&D processes, healthcare delivery and regulatory practice.

The following articles describe the value that the Innovative Medicines Initiative (IMI) and Innovative Health Initiative (IHI) have for research foundations, and showcase how IMI and IHI are shaping the future of translational safety and enhance regulatory engagement.

Collectively, they underscore a shared vision: that well-structured partnerships can accelerate scientific progress, improve patient outcomes, and foster more resilient, responsive healthcare systems.

Delivering regulatory impact from consortium-based projects 16 June 2025 (Nature Reviews Drug Discovery)

The strategic value of philanthropic organisations in public-private partnerships - the example... 12 June 2025 (IHI)

Innovative Medicines Initiative public–private partnerships to enhance translational safety... 22 May 2025 (Nature Reviews Drug Discovery)

Unleashing Europe’s biotech prowess requires radical reinvention

Today, Europe is home to strong research universities and prodigious talent, but it has been losing ground, particularly to the U.S. and China. In the 1990s, for example, half of all new medicines originated in Europe — now, the figure’s down to one in five. And the life sciences is just one of many such industries.

Europe must reverse this trend, and now is the time to act.

Read the POLITICO article here.

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶